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SUPPLEMENTARY MATERIAL 
Search strategy  
(Ovid MEDLINE, EMBASE, Evidence Based Medicine (EBM), and Cochrane Library)  
For EMBASE, MEDLINE, and EBM trials 
#1: (axial spondyloarthritis).mp OR (ankylosing spondylitis).mp OR axspa.mp OR as.mp OR 
spondyloarthritis/exp OR spondyloathritis.mp. 
#2: (biologic$ ADJ5 treatment).mp OR (biologic$ ADJ5 therapy).mp OR (biologic$ ADJ5 agent).mp OR 
(anti$tnf).mp OR (tnf inhibitor).mp OR (anti tumo$r necrosis factor).mp OR biologic* OR (tnfi).mp OR 
etanercept.mp OR infliximab.mp OR anakinra OR adalimumab.mp OR abatacept.mp OR 
golimumab.mp OR rituximab.mp OR certolizumab.mp OR tocilizumab.mp OR (anti ADJ tumo$r ADJ 
necrosis ADJ factor).tw. 
#3: (fatigue).mp OR fatigue/exp OR tiredness.mp.  
#1 AND #2 AND #3 
Supplementary Table S1 – BSRBR-AS study: characteristics of those included in the current analysis 





 mean(SD)/N(%) mean(SD)/N(%) 
Gender (male) 693 (69%) 962 (68%) 
Age, mean years* 51.5 (14.4) 45.7 (13.9) 
Disease duration, mean years 29.1 (12.1) 28.4 (11.1) 
Disease classification*   
modified New York 729 (73%) 883 (62%) 
ASAS imaging (not mNY) 234 (23%) 474 (33%) 
ASAS clinical only 35 (4%) 65 (5%) 
Extra-articular manifestations   
uveitis present 252 (25%) 316 (22%) 
inflammatory bowel disease present 102 (10%) 145 (10%) 
psoriasis present 107 (11%) 157 (11%) 
BASDAI * 
(scored 0 (best) to 10 (worst)) 4.5 (2.5) 5.2 (2.5) 
BASFI * 
(scored 0 (best) to 10 (worst)) 4.4 (2.9) 4.9 (2.9) 
BASMI * 
(scored 0 (best) to 10 (worst)) 4.0 (1.9) 3.8 (2.1) 
Fatigue * 
(scored 0 (best) to 11 (worst) 3.9 (3.6) 4.5 (3.8) 
* statistically significant difference between those included and excluded (p ≤ 0.05) 
ASAS – assessment of spondyloarthritis; BASDAI – bath ankylosing spondylitis disease activity index; 





Supplementary Table S2 Characteristics of studies eligble for meta-analysis, reporting the impact of biological therapy on fatigue in patients with axSpA 
Authors Year Study 
Location 

















AS patients with 
active spondylitis 
(morning 
stiffness >45 min, 
IBP, 
moderate/high 




Double blind, placebo 
controlled randomized 
study. 
40 20 20 Fatigue Severity 
Scale* 










GP or local AS 
support group. 
 
Mixed methods model 
comparing those 
starting an anti-TNF 
therapy compared to 
those who were not.  
Fatigue assessed by 3 
monthly 
questionnaire. 
235 39 196 BASDAI fatigue 
item 












(not mNY), aged 




double blind, 2 period, 
randomised phase IIIB 
clinical controlled trial. 







of >3 month to <5 
years and active 
disease (defined 
as BASDAI ≥4.  
Double blinded to 
week 12 and open 
label to week 24.  















NSAIDs.  Failure 





controlled, Phase III 
study.  Double blinded 
to week 12. Weeks 12-
20 open label for non-
responders. Full open 
label after week 24 up 
to 5 years. 
315 208 107 BASDAI fatigue 
item 
Adalimumab 12 & 24 
weeks 
*Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus 
erythematosus. Arch Neurol 1989;46:1121–3. 
** Follow-up which included a measure of fatigue 
IPB: inflammatory back pain

